Cargando…
Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
To evaluate the role of the vitreous in the management of diabetic macular edema with ranibizumab intravitreal injections in a pro re nata regimen. Prospective study of 50 consecutive eyes with diabetic macular edema treated with ranibizumab and 12 months of follow-up. Primary endpoint: to assess di...
Autores principales: | Pessoa, Bernardete, Leite, João, Heitor, João, Coelho, João, Monteiro, Sérgio, Coelho, Constança, Figueira, João, Meireles, Angelina, Melo-Beirão, João Nuno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630028/ https://www.ncbi.nlm.nih.gov/pubmed/34845300 http://dx.doi.org/10.1038/s41598-021-02532-4 |
Ejemplares similares
-
Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa, Bernardete, et al.
Publicado: (2021) -
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
por: Coelho, João, et al.
Publicado: (2019) -
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021) -
Enzymatic vitreolysis for the treatment of tractional diabetic macular edema
por: Pessoa, Bernardete, et al.
Publicado: (2019) -
Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)